Cim Investment Management Inc. Buys New Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

Cim Investment Management Inc. purchased a new position in SIGA Technologies, Inc. (NASDAQ:SIGA) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 25,825 shares of the company’s stock, valued at approximately $196,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale bought a new stake in shares of SIGA Technologies in the 2nd quarter worth approximately $40,000. Steward Partners Investment Solutions LLC bought a new position in shares of SIGA Technologies in the fourth quarter valued at $58,000. Bayesian Capital Management LP bought a new position in shares of SIGA Technologies in the first quarter valued at $97,000. AQR Capital Management LLC acquired a new stake in shares of SIGA Technologies during the 2nd quarter valued at $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of SIGA Technologies by 38.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock worth $104,000 after acquiring an additional 3,829 shares in the last quarter. 55.40% of the stock is owned by institutional investors and hedge funds.

SIGA Technologies Stock Up 0.3 %

Shares of NASDAQ SIGA opened at $6.96 on Friday. SIGA Technologies, Inc. has a 52-week low of $4.26 and a 52-week high of $12.83. The stock has a market capitalization of $496.74 million, a price-to-earnings ratio of 6.33 and a beta of 0.91. The stock’s fifty day simple moving average is $8.85 and its 200 day simple moving average is $8.38.

SIGA Technologies (NASDAQ:SIGA) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.03 earnings per share (EPS) for the quarter. SIGA Technologies had a return on equity of 51.40% and a net margin of 48.55%. The firm had revenue of $21.81 million for the quarter. During the same quarter in the previous year, the firm posted ($0.04) EPS. As a group, analysts anticipate that SIGA Technologies, Inc. will post 1.01 earnings per share for the current year.

SIGA Technologies Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.